Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism.
作者： Thomas Nyström , Adrian T. Gonon , Åke Sjöholm , John Pernow
DOI: 10.1016/J.REGPEP.2004.08.024
关键词: Receptor antagonist 、 Endothelial dysfunction 、 Diabetes mellitus 、 Internal medicine 、 Endothelium 、 Receptor 、 Type 2 diabetes 、 Type 2 Diabetes Mellitus 、 Nitric oxide 、 Medicine 、 Endocrinology
摘要: A lot of interest has engendered in glucagon-like peptide-1 (GLP-1) as an emerging new drug the treatment type 2 diabetes. GLP-1 exerts several effects that reduce glycemia diabetes patients. We recently also demonstrated ameliorates endothelial dysfunction mellitus patients with established coronary heart disease, suggesting a important cardioprotective role for GLP-1. Because hypertension is overrepresented and adversely influencing survival, we have now investigated direct on vascular beds rat organ bath model. It was found relaxed femoral artery rings dose-response manner. The relaxant effect from completely inhibited by specific receptor antagonist, exendin(9-39). Neither nitric oxide (NO) synthase inhibitor, N-nitro-L-arginine, nor removing endothelium, affected effect. In conclusion, report action GLP-1, relaxing conduit vessels independently NO endothelium.
elsevier.com
sci-hub.se 参考文章(18)
Mark Gutniak, Cathrine Ørkov, Jens J Holst, Bo Ahrén, Suad Efendić, None, Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. The New England Journal of Medicine. ,vol. 326, pp. 1316- 1322 ,(1992) , 10.1056/NEJM199205143262003
B P Bullock, R S Heller, J F Habener, Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. ,vol. 137, pp. 2968- 2978 ,(1996) , 10.1210/ENDO.137.7.8770921
Lene Hansen, Bolette Hartmann, Hitoshi Mineo, Jens J Holst, None, Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum Regulatory Peptides. ,vol. 118, pp. 11- 18 ,(2004) , 10.1016/J.REGPEP.2003.10.021
M. A. Nauck, D. Wollschläger, J. Werner, J. J. Holst, C. Ørskov, W. Creutzfeldt, B. Willms, Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia. ,vol. 39, pp. 1546- 1553 ,(1996) , 10.1007/S001250050613
M. K. Gutniak, H. Larsson, S. J. Heiber, O. T. Juneskans, J. J. Holst, B. Ahren, Potential Therapeutic Levels of Glucagon-Like Peptide I Achieved in Humans by a Buccal Tablet Diabetes Care. ,vol. 19, pp. 843- 848 ,(1996) , 10.2337/DIACARE.19.8.843
Heiko A Golpon, Annette Puechner, Tobias Welte, Peter V Wichert, Christian O Feddersen, Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regulatory Peptides. ,vol. 102, pp. 81- 86 ,(2001) , 10.1016/S0167-0115(01)00300-7
W. O. C. Creutzfeldt, N. Kleine, B. Willms, C. Orskov, J. J. Holst, M. A. Nauck, Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patients Diabetes Care. ,vol. 19, pp. 580- 586 ,(1996) , 10.2337/DIACARE.19.6.580
Sari Mäkimattila, Hannele Yki-Järvinen, Endothelial dysfunction in human diabetes Current Diabetes Reports. ,vol. 2, pp. 26- 36 ,(2002) , 10.1007/S11892-002-0054-X
J. Rachman, R.C. Turner, Drugs on the Horizon for Treatment of Type 2 Diabetes Diabetic Medicine. ,vol. 12, pp. 467- 478 ,(1995) , 10.1111/J.1464-5491.1995.TB00526.X
Todd D. Williams, Joel K. Elmquist, Charlotte E. Lee, Jacob N. Marcus, Hiroshi Yamamoto, Clifford B. Saper, Daniel J. Drucker, J. Michael Overton, Marisol E. Lopez, Laurie Baggio, Anthony N. Hollenberg, Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons Journal of Clinical Investigation. ,vol. 110, pp. 43- 52 ,(2002) , 10.1172/JCI15595